Ignite Creation Date:
2025-12-25 @ 1:01 AM
Ignite Modification Date:
2025-12-25 @ 11:15 PM
Study NCT ID:
NCT06448793
Status:
RECRUITING
Last Update Posted:
2025-12-04
First Post:
2024-06-04
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D002289', 'term': 'Carcinoma, Non-Small-Cell Lung'}], 'ancestors': [{'id': 'D002283', 'term': 'Carcinoma, Bronchogenic'}, {'id': 'D001984', 'term': 'Bronchial Neoplasms'}, {'id': 'D008175', 'term': 'Lung Neoplasms'}, {'id': 'D012142', 'term': 'Respiratory Tract Neoplasms'}, {'id': 'D013899', 'term': 'Thoracic Neoplasms'}, {'id': 'D009371', 'term': 'Neoplasms by Site'}, {'id': 'D009369', 'term': 'Neoplasms'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}]}, 'interventionBrowseModule': {'meshes': [{'id': 'D013812', 'term': 'Therapeutics'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'OTHER', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 55}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'RECRUITING', 'startDateStruct': {'date': '2024-11-25', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-11', 'completionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-11-27', 'studyFirstSubmitDate': '2024-06-04', 'studyFirstSubmitQcDate': '2024-06-04', 'lastUpdatePostDateStruct': {'date': '2025-12-04', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2024-06-07', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2026-06-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Responses to qualitative interview questions', 'timeFrame': 'Day 1', 'description': 'Interview questions designed to gather insights into diagnosis, symptoms, current treatments, perspectives on treatment features and test for mock preferences tasks. The interview will take 15 minutes to complete.'}, {'measure': 'Patient sociodemographic', 'timeFrame': 'Day 1'}, {'measure': 'Patient clinical characteristics', 'timeFrame': 'Day 1'}]}, 'oversightModule': {'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'keywords': ['Non-small Cell Lung Cancer (NSCLC)'], 'conditions': ['Non-small Cell Lung Cancer (NSCLC)']}, 'referencesModule': {'seeAlsoLinks': [{'url': 'https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html', 'label': 'BMS Clinical Trial Information'}, {'url': 'https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts', 'label': 'FDA Safety Alerts and Recalls'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to investigate the perspectives and preferences of patients and healthcare professionals (medical oncologists, pneumologists, thoracic surgeons) regarding treatment options in the resectable non-small cell lung cancer (NSCLC) setting'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Adults participants with a diagnosis of resectable NSCLC and physicians treating patients with resectable NSCLC residing in US, Germany or Japan.', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\nPatients\n\n* Aged ≥18 years at the time of enrollment in the study\n* Resident of the US, Germany, or Japan\n* Able to read, speak, and understand English, German or Japanese\n* Diagnosed with resectable phase II to IIIB non-small cell lung cancer (NSCLC)\n\nPhysicians\n\n* Resident of the US, Germany, or Japan\n* Lung cancer-treating physician specialized in one of the following medical areas: oncology, pneumonology, thoracic surgery, or radiology\n* Treated at least three new patients with resectable NSCLC in the past year\n\nExclusion Criteria:\n\nPatients\n\n* Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)\n* Being diagnosed with another malignancy alongside NSCLC\n* Not willing to be audio-recorded during the interview\n\nPhysicians\n\n* Appears to have sensory and/or cognitive impairment(s) that could interfere with their ability to provide online and/or verbal consent, or complete any other interview activities (based on screener judgment)\n* Not willing to be audio-recorded during the interview'}, 'identificationModule': {'nctId': 'NCT06448793', 'briefTitle': 'Patient and Physician Preference Study in Resectable, Non-small Cell Lung Cancer Treatments', 'organization': {'class': 'INDUSTRY', 'fullName': 'Bristol-Myers Squibb'}, 'officialTitle': 'Patient and Physician Preferences for Potentially Resectable, Non-metastatic Non-small Cell Lung Cancer Treatments', 'orgStudyIdInfo': {'id': 'CA209-1384'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC)', 'interventionNames': ['Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies']}, {'label': 'Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients', 'interventionNames': ['Drug: Approved Non-small Cell Lung Cancer (NSCLC) therapies']}], 'interventions': [{'name': 'Approved Non-small Cell Lung Cancer (NSCLC) therapies', 'type': 'DRUG', 'description': 'As prescribed by treating physician', 'armGroupLabels': ['Patients with a diagnosis of resectable non-small cell lung cancer (NSCLC)', 'Physicians currently treating resectable non-small cell lung cancer (NSCLC) patients']}]}, 'contactsLocationsModule': {'locations': [{'city': 'London', 'status': 'RECRUITING', 'country': 'United Kingdom', 'facility': 'Evidera', 'geoPoint': {'lat': 51.50853, 'lon': -0.12574}}], 'centralContacts': [{'name': 'BMS Study Connect Contact Center www.BMSStudyConnect.com', 'role': 'CONTACT', 'email': 'Clinical.Trials@bms.com', 'phone': '855-907-3286'}, {'name': 'First line of the email MUST contain NCT # and Site #.', 'role': 'CONTACT'}], 'overallOfficials': [{'name': 'Bristol-Myers Squibb', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Bristol-Myers Squibb'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Bristol-Myers Squibb', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}